

A Review on Obesity from Mother to Child

Indrani P*

Sri Indu College of Pharmacy, Hyderabad, India

Review Article

Received: 29/08/2016

Revised: 30/08/2016

Accepted: 02/09/2016

*For Correspondence

Indrani P, M-pharmacy
(pharmacology), Sri indu college
of pharmacy, Hyderabad, India

E-mail: peddi.indrani@gmail.com

Keywords: Obesity, Pregnancy,
Embryo, Insulin

ABSTRACT

Obesity is a therapeutic condition in which abundance muscle to fat quotients has aggregated to the degree that it might negatively affect health. Individuals are for the most part thought to be large when their body mass file (BMI), an estimation acquired by separating a man's weight by the square of the individual's stature, is more than 30 kg/m², with the reach 25–30 kg/m² characterized as overweight. Some East Asian nations use lower values. Obesity improves the probability of different illnesses, especially coronary illness, type-2 diabetes, obstructive rest apnea, certain sorts of disease, and osteoarthritis.

INTRODUCTION

Obesity is mostly caused by excess food consumption, absence of physical action, and hereditary. A couple cases are brought on fundamentally by genes, disorders in endocrine glands, prescriptions, or emotional sickness. Confirmation to bolster the perspective that obese individuals eat little yet put on weight because of a moderate digestion system is not for the most part upheld. By and large, obese individuals have more noteworthy vitality consumption than their slight partners because of the vitality required maintain an increased body mass [1-25].

Scientists now have shown that umbilical cells from offspring of obese or overweight moms show debilitated articulation of key qualities managing cell vitality and digestion system, contrasted with comparative cells from children of non-obese moms. Moms Gaining Weight Excessively During Pregnancy May Put Newborn Babies At Risk Of Childhood Obesity [26-33].

Researchers have long realized that newborn children destined to ladies who are large show higher dangers of stoutness, however they don't completely comprehend what supports those dangers. Late studies have exhibited that umbilical cells from offspring of large or overweight moms show debilitated articulation of key qualities controlling cell vitality and digestion system, contrasted with comparable cells from infants of non-obese moms [34-45].

Studies may make ready toward enhanced human services, both prior and then afterward birth, for kids at elevated danger of weight, the expanded dangers of stoutness might be driven by helped levels of specific lipids (fats and different substances that are not dissolvable in water) in the maternal blood that courses through the umbilical line [46-60].

The researchers gathered umbilical cells from the vein that takes oxygen and different supplements from the placenta to the embryo. These give a window into the supplements and metabolites that are originating from the mother into the newborn child. These cells, expanded weight in the moms related with lower articulation of qualities managing mitochondria and of different qualities directing the creation and digestion system of lipids. This proposes as of now during childbirth there are distinguishable metabolic annoyances coming about because of maternal stoutness. Changes in these cells were like some known not in obesity, insulin resistance and type 2 diabetes [61-80].

At the point when the analysts followed up by analyzing fetal blood from the umbilical vein, found that the newborn children of obese moms had altogether larger amounts of numerous lipids that are known not metabolically harmful, as immersed unsaturated fats, Fat tissues in the obese moms may shed unsaturated fats that advance into the fetal blood and make a sort of fuel over-burden for the developing life If we could think of custom fitted

mediations like taking vitamins, doing exercise routinely to minimize weight or diabetes hazard in newborns. Moms and human services suppliers additionally could precisely screen the development examples and sustenance of kids at danger of obesity, both in the initial two years of life and a while later. The danger of endless ailments isn't an unavoidable reality during childbirth; there are a wide range of periods in which long lasting ailment danger can be adjusted [81-100].

REFERENCES

1. Jeon JH, et al. A novel adipokine CTRP1 stimulates aldosterone production. *FASEB J.* 2008;22:1502-1511.
2. Lasser G, et al. C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. *Blood.* 2005;7:423-430.
3. Kim KY, et al. Tumor necrosis factor-alpha and interleukin-1beta increases CTRP1 expression in adipose tissue. *FEBS Lett.* 2006;580:3953-3960.
4. Davis KE and Scherer PE. Adiponectin: no longer the lone soul in the fight against insulin resistance. *Biochem J.* 2008;416:e7-9.
5. Wong GW, et al. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. *Biochem J.* 2008;416:161-177.
6. Chuang SY, et al. Presence and progression of abdominal obesity are predictors of future high blood pressure and hypertension. *Am J Hypertens.* 2006;19:788-795.
7. Bomback AS and Klemmer PJ. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. *Am J Nephrol.* 2009;30:140-146.
8. Chuang SY, et al. Presence and progression of abdominal obesity are predictors of future high blood pressure and hypertension. *Am J Hypertens.* 2006;19:788-795.
9. Kurukulasuriya LR, et al. Hypertension in obesity. *Endocrinology & Metabolism Clinics of North America.* 2008;37:647-662.
10. Lindhardt M, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. *BMJ Open.* 2016;6:e010310.
11. Kitada M, et al. A very-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity. *Diabetologia.* 2016;59:1307-1317.
12. Hoffmann F, et al. The effect of diabetes on incidence and mortality in end-stage renal disease in Germany. *Nephrol Dial Transplant.* 2011;26:1634-1640.
13. Xu H, et al. Association of aldosterone synthase (CYP11B2) -344 T/C polymorphism with diabetic nephropathy: A meta-analysis. *J Renin Angiotensin Aldosterone Syst.* 2016;17.
14. Zain M and Awan FR. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy. *Pak J Pharm Sci.* 2014;27:1379-1391.
15. Kang YS and Cha DR. Aldosterone and diabetic kidney disease. *CurrDiab Rep.* 2009;9:453-459.
16. Kamijo-Ikemori A, et al. Novel urinary biomarkers in early diabetic kidney disease. *CurrDiab Rep.* 2014;14: 513.
17. Majewski C and Bakris GL. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy. *CurrDiab Rep.* 2016;16:24.
18. Chalupova L, et al. Development of a novel enzyme-linked immunosorbent assay (ELISA) for measurement of serum CTRP1: a pilot study: measurement of serum CTRP1 in healthy donors and patients with metabolic syndrome. *Clin Biochem.* 2013;46:73-78.

19. Pan X, et al. Circulating complement-C1q TNF-related protein 1 levels are increased in patients with type 2 diabetes and are associated with insulin sensitivity in Chinese subjects. *PLoS One*. 2014;9:e94478.
20. Xin Y, et al. Elevated circulating levels of CTRP1, a novel adipokine, in diabetic patients. *Endocr J*. 2014;61:841-847.
21. Chalupova L, et al. CTRP1: A Molecular Link between Obesity and Hypertension . *J Mol Biomark Diagn*. 2016;7:289.
22. Kolker E, et al. Toward more transparent and reproducible omics studies through a common metadata checklist and data publications. *OMICS*. 2014;18:10-14.
23. Zhao F, et al. A quantitative analysis of the mass media coverage of genomics medicine in China: a call for science journalism in the developing world. *OMICS*. 2014;18:222-230.
24. Chakrabarti R. Pharmacotherapy of obesity: emerging drugs and targets. *Expert Opin Ther Targets*. 2009;13:195-207.
25. Schadt EE, et al. Advances in systems biology are enhancing our understanding of disease and moving us closer to novel disease treatments. *Genetica*. 2009;136:259-269.
26. Lewis CE, et al. Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. *Circulation*. 2009;119:3263-3271.
27. Allison DB, et al. Microarray data analysis: from disarray to consolidation and consensus. *Nat Rev Genet*. 2006;7:55-65.
28. Fontaine KR, et al. Years of life lost due to obesity. *JAMA*. 2003;289:187-193.
29. Andreasen CH and Andersen G. Gene-environment interactions and obesity-further aspects of genomewide association studies. *Nutrition*. 2009;25:998-1003.
30. LeRoith D, et al. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. *Exp Clin Endocrinol Diabetes*. 2008;11 Suppl 1:S4-S6.
31. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech*. 2009;2:231-237.
32. Barrett T, et al. NCBI GEO: mining tens of millions of expression profiles--database and tools update. *Nucleic Acids Res*. 2007;35:D760-765.
33. Reisin E and Jack AV. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. *Med Clin North Am*. 2009;93:733-751.
34. Korner J, et al. Regulation of energy homeostasis and health consequences in obesity. *Am J Med*. 2009;122:S12-18.
35. Schoeller DA. The energy balance equation: looking back and looking forward are two very different views. *Nutr Rev*. 2009;67:249-254.
36. Roche HM, et al. The metabolic syndrome: the crossroads of diet and genetics. *Proc Nutr Soc*. 2005;64: 371-377.
37. Remely M, et al. Obesity: epigenetic regulation recent observations. *Biomol Concepts*. 2015;6:163-175.
38. Bell CG, et al. The genetics of human obesity. *Nat Rev Genet*. 2005;6:221-234.
39. Herbert A. The fat tail of obesity as told by the genome. *Curr Opin Clin Nutr Metab Care*. 2008;11:366-370.
40. Nobrega MA. TCF7L2 and glucose metabolism: time to look beyond the pancreas. *Diabetes*. 2013;62:706-708.
41. Zhou Y, et al. TCF7L2 is a master regulator of insulin production and processing. *Hum Mol Genet*. 2014;23: 6419-6431.
42. Boj SF, et al. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. *Cell*. 2012;151:1595-1607.

43. Shao W, et al. The Wnt signaling pathway effector TCF7L2 controls gut and brain proglucagon gene expression and glucose homeostasis. *Diabetes*. 2013;62:789-800.
44. Yang J, et al. FTO genotype is associated with phenotypic variability of body mass index. *Nature*. 2012;490: 267-272.
45. Thrift AP, et al. Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk. *Cancer Epidemiol Biomarkers Prev*. 2015;24:1024-1031.
46. Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015;518:197-206.
47. Yi F, et al. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. *J BiolChem*. 2005;280:1457-1464.
48. Damcott CM, et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. *Diabetes*. 2006;55:2654-2659.
49. Saxena R, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. *Diabetes*. 2006;55:2890-2895.
50. Dolinoy DC, et al. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. *Proc Natl Acad Sci U S A*. 2007;104:13056-13061.
51. Roseboom TJ, et al. Effects of prenatal exposure to the Dutch famine on adult disease in later life: an overview. *Molecular and cellular endocrinology*. 2001;185:93-98.
52. Haslberger GH, et al. Integration of OMICS Data for Obesity. *J Diab Obes*. 2015;2:1-9
53. Timpson NJ, et al. Adiposity-related heterogeneity in patterns of type 2 diabetes susceptibility observed in genome-wide association data. *Diabetes*. 2009;58:505-510.
54. Hindorf LA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci U S A*. 2009;106:9362-9367.
55. Steinthorsdottir V, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. *Nat Genet*. 2007;39:770-775.
56. Johnson AD and O'Donnell CJ. An open access database of genome-wide association results. *BMC Med Genet*. 2009;10:6.
57. Heard-Costa NL, et al. NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. *PLoS Genet*. 2009;5:e1000539.
58. Cotsapas C, et al. Common body mass index-associated variants confer risk of extreme obesity. *Hum Mol Genet*. 2009;18:3502-3507.
59. Weedon MN, et al. A common variant of HMGA2 is associated with adult and childhood height in the general population. *Nat Genet*. 2007;39:1245-1250.
60. Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science*. 2007;316:889-894.
61. Brettfield C, et al. Integration and Weighing of Omics Data for Obesity. *J Diabetes Metab*. 2016;7:690.
62. Rohmah Z, et al. Anti-Obesity effects of Lipid Extract from Sea-Reared of Rainbow Trout (*Oncorhynchus mykiss*) Fed with Sea Squirt (*Halocynthia roretzi*) Tunic's Carotenoids and CLA. *J Nutr Food Sci*. 2016;6:525.
63. Aziz IMA, et al. Impact of Obesity on Gastrointestinal Quality of Life among Patients with Upper Gastrointestinal Disorders. *J Gastrointest Dig Syst*. 2016;6:437.
64. Míguez MJ, et al. Obesity, Cytokines and Cognition across the Lifespan among People Living with HIV. *J AIDS Clin Res*. 2016;7:593.
65. Szybinski Z. Primary Prevention of Obesity and Type 2 Diabetes Mellitus. *Epidemiology (Sunnyvale)*. 2016;6:243.

66. Panneerselvam S, et al. Protective Effect of Soy Isoflavones (from *Glycine max*) on Adipose Tissue Oxidative Stress and Inflammatory Response in an Experimental Model of Post-menopausal Obesity: The Molecular Mechanisms. *Biochem Anal Biochem*. 2016;5:266.
67. You W and Henneberg M. Meat in Modern Diet, Just as Bad as Sugar, Correlates to Worldwide Obesity: An Ecological Analysis. *J Nutr Food Sci*. 2016;6:517.
68. Birketvedt GS, et al. A Dietary Supplement in Combination with an Education Plan and a Long-Term Follow-up Significantly Decrease Blood Pressure, Body Weight and Body Fat. *J Nutr Food Sci*. 2016;6:512.
69. Faghri PD and Budden J. Overtime, Shift Work, Poor Sleep and the Effects on Obesity: A Public Health Problem. *J Nutr Disorders Ther*. 2008;6:e126.
70. Dominici C, et al. The Importance of the "Obesity Paradox" in Cardiac Surgery. *Angiol*. 2016;4:e115.
71. Horton A. Obesity and Structural and Cognitive-behavioral Approaches to Therapy. *Anat Physiol*. 2016;6:220.
72. Morales MCE, et al. The Prospective Antiobesity Effect of Capsaicin Synthetic Analogs: A Matter of Weight. *Med chem (Los Angeles)*. 2016;6:365-371.
73. Musil D. Chronic Venous Disease, Obesity and the Risk of Venous Thromboembolism in a Czech Population. *J Obes Weight Loss Ther*. 2016;6:310.
74. Debnath M and Sarkar S. Obesity Induced Metaflammation: Pathophysiology and Mitigation. *J Cytokine Biol*. 2016;1:104.
75. Agabio R, et al. Oxytocin Nasal Spray in the Treatment of Binge Eating Disorder and Obesity: A Pilot, Randomized, Double-Blind Trial. *Clin Pharmacol Biopharm*. 2016;5:155.
76. Payne AJ, et al. Effect of Environmental Factors on Obesity: A Quantile Regression Approach. *J Biom Biostat*. 2016;7:293.
77. Mohamed WS and Ashour AS. Effect of Obesity on Albino Rat Kidney. *Endocrinol Metab Syndr*. 2016;5:226.
78. Bharadwaz A and Madhab G. Maternal Obesity: An Important Contributor to Congenital Anomalies, Infant and Child Mortality with Negative Economic Impact. *J Preg Child Health*. 2016;2:213.
79. Arisaka O, et al. Early Adiposity Rebound and Small Dense Low-Density Lipoprotein in Childhood Obesity. *J Obes Weight Loss Ther*. 2016;6:301.
80. Leticia GS, et al. Preliminary Evaluation of a Nutraceutical Product Made with Residue of *Cocos Nucifera* for Use in the Treatment of Obesity. *Transl Med (Sunnyvale)*. 2016;6:166.
81. Bidaki R and Haghighi FS. Recurrent Suicide Attempt in Two Sisters with Non-segmental Vitiligo and Obesity: A Rare Case Report. *Pigmentary Disorders*. 2016;3:235.
82. Ibraimov AI. Chromosomal Q-Heterochromatin Polymorphism in Patients with Alimentary Obesity. *Biol Med (Aligarh)*. 2016;8:275.
83. Jahan F. Obesity in Women: A Challenge in Arab World. *J Women's Health Care*. 2016;5:e116.
84. Shoar Z, et al. Maternal Obesity, Maternal Gestational Diabetes Mellitus, and Maternal and Neonatal Outcomes. *J Obes Weight Loss Ther*. 2016;6:292.
85. Wang B, et al. Dysglycemia and Dyslipidemia Models in Nonhuman Primates: Part II. Model of Naturally Occurring or Experimental Obesity. *J Diabetes Metab*. 2016;7:641.
86. Roever L and ACP C. "Obesity paradox" and Cardiovascular Disease: Myth or a Better Clinical Outcome? . *Evidence Based Medicine and Practice*. 2016;1:e102.
87. Atapattu PM. Obesity at Menopause: An Expanding Problem. *J Pat Care*. 2015;1:103.
88. Mussa BM, et al. Prevalence of Hypertension and Obesity among Emirati Patients with Type 2 Diabetes. *J Diabetes Metab*. 2016;7:638.
89. Carsote M, et al. Obesity and Fractures: Between Black and White Aspects. *J Obes Weight Loss Ther*. 2015;5:288.

90. Nikose SS, et al. Outcome Analysis of Obesity in Trauma Surgery Related to Closed Injuries of Lower Limb in Orthopedic Surgery. *J Obes Weight Loss Ther.* 2015;5:287.
91. Wen LM. Obesity in Young Children: What Can We Do About?. *J Obes Weight Loss Ther.* 2015;5:286.
92. Korczyk D, et al. Brain Natriuretic Peptide Clearance in Patients with Obesity and Insulin Resistance - a Mechanistic Study. *J Clin Case Rep.* 2015;5:647.
93. Butrón PL, et al. Association between Cardiovascular Disease, Cerebrovascular Disease and Overweight and Obesity among Adults in Puerto Rico. *J Trop Dis.* 2015;S1-005.
94. Wimalawansa SJ. Preventing Long-Term Complications of Obesity, Type 2 Diabetes, and Metabolic Syndrome: Common Sense Approach *Endocrinol Metab Syndr.* 2015;4:206.
95. Aldeen T and Adewale A. Obesity and Psoriasis: Can Bariatric Surgery Trigger Psoriasis. *J Clin Exp Dermatol Res.* 2015;6:302.
96. Sindhu S, et al. Changes in the Adipose Tissue Expression of CD86 Costimulatory Ligand and CD163 Scavenger Receptor in Obesity and Type-2 Diabetes: Implication for Metabolic Disease. *J Glycomics Lipidomics.* 2015;5:134.
97. Villard A, et al. Diagnostic Value of Cell-free Circulating Micrnas for Obesity and Type 2 Diabetes: A Meta-Analysis. *J Mol Biomark Diagn.* 2015;6:251.
98. Kazan M and Karalti İ. The Association between Obesity and Cancer. *Endocrinol Metab Syndr.* 2015;4:196.
99. Roever L. Pancreatic Steatosis: Is it Related to Obesity, Diabetes Mellitus and Metabolic Syndrome. *Pancreat Disord Ther.* 2015;5:e139.
100. Hamma SA, et al. Oxidative Stress in Algerian Adults Obesity. *J Metabolic Syndr.* 2015;4:188.